BOD 0.00% 2.4¢ bod science limited

andrew forrest-backed biotech lists on asx, page-6

  1. 5,278 Posts.
    lightbulb Created with Sketch. 29
    Further Agent, you should also know that BRW Rich Listers, the Lieberman Family are also invested Coridon, and also Allied Medical was a spin-off from Fortescue so rest assured, BioMD would have some impressive investors on their register now.

    When people suggest the idea of diversification rules being applied to investing in stocks one could also suggest that an investment in BioMD is essentially taking care of that, investing in 4 diversified businesses:

    BioMD
    Allied
    Coridon
    Medevco

    Just noticed the SMH ran this story with an interesting comment made by Mr Rodne yesterday

    "Allied's former chief executive and now its managing director, Lee Rodne, said he hoped to bring bioMD's lead product, CardioCel, a soft-tissue patch that repairs conditions such as holes in the heart, to the market by the end of the year or early next year.

    Successful phase II trials had been completed and the regulatory application process had begun, he said.
    Click HERE for SMH article

    Worth noting that VLA recently ran from 4c to 10c on news of their FDA regulatory application for only a phaseII clinical trial for their vaccine within the over-crowded global arena of Melanoma skin cancer trials. I can tell you right now that GSK and Novartis have more advanced and very promising BRAF and MEK inhibitors for advanced melanoma currently in phaseIII trial so I don't fancy VLA's chances of commercial success at all. BioMD have a cardiocel patch already more advanced than anything else currently within this very fast growing global market. And I've been very content putting my money where my mouth is ;)

    Key Commercialisation Milestnoes in progress - BioMD

    * FDA application to follow TGA/CE ~ Q2, 2011

    * Global Heart Valve Project Completed ~ Q2,2011

    * Commercial product Cardiocel ready for AUST & ASIAN markets ~ Q2,2011

    * Cardiocel patch distribution agreement for Europe ~ Q3.2011

    * Feasibility study plan continuing with undisclosed global heart valve company
 
watchlist Created with Sketch. Add BOD (ASX) to my watchlist
(20min delay)
Last
2.4¢
Change
0.000(0.00%)
Mkt cap ! $4.256M
Open High Low Value Volume
0.0¢ 0.0¢ 0.0¢ $0 0
BOD (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.